Why the study?
Does perindopril reduce cardiovascular events and mortality in hypertensive patients?
Does perindopril reduce cardiovascular events and mortality in hypertensive patients?
Perindopril, particularly in combination with amlodipine or indapamide, is an effective treatment for hypertension that reduces cardiovascular mortality and events.
Answers are grounded in this paper and cite their sources.
Supports perindopril/amlodipine over atenolol-based regimens in hypertension; reinforces guideline recommendations and extends ACEI/CCB outcome evidence.
INTRODUCTION: Treatment of hypertension is fundamental for the prevention of cardiovascular events and mortality. This review focuses on the specific benefits of the ACE inhibitor perindopril. AREAS COVERED: A systematic literature search is undertaken for supporting the pharmacological proprieties and clinical efficacy of perindopril in the treatment of hypertension. Good tissue penetration, strong affinity for ACE and a long duration of action support the dose-dependent blood pressure lowering efficacy. Perindopril in combination with amlodipine significantly reduced total and cardiovascular mortality as compared to atenolol/diuretic in large-scale clinical trials of hypertensive patients. A greater reduction in blood pressure variability, central blood pressure and specific vascular protective proprieties of perindopril (improvement in arterial stiffness and endothelial function) might explain these results. Cardiovascular prevention with perindopril, in combination with indapamide, has been also shown in the elderly and patients with diabetes, cardio- and cerebrovascular diseases. EXPERT OPINION: Perindopril is effective and safe for blood pressure control with a dose-dependent effect. Combination therapy with indapamide or amlodipine reduces cardiovascular events and mortality in hypertensive patients. Pharmacological proprieties and results of clinical trials support the choice of perindopril as an appropriate treatment for hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Lorenzo Ghiadoni (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: